Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

45.31 -0.36 (-0.78%)
Streaming Delayed Price Updated: 12:39 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety
As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock to Present at Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Why Is Scholar Rock Holding Stock Climbing Today? ↗
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab. 
Via Benzinga
News headline image
Why Did Scholar Rock Soar 26% Today? ↗
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 
Via Stocktwits
Topics Earnings
News headline image
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗
Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss. 
Via Chartmill
News headline image
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten. 
Via Benzinga
News headline image
What to Expect from Scholar Rock Holding's Earnings ↗
 
Via Benzinga
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
3 Beaten-Down Stocks With Rebound Potential This Earnings Season ↗
Via MarketBeat
News headline image
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Alpha Buying: 3 Stocks With Sky-High Insider Confidence ↗
 
Via Benzinga
News headline image
Why Scholar Rock Stock Got Socked on Monday ↗
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects. 
Via The Motley Fool
Topics Earnings
News headline image
Why Is Scholar Rock Stock Trading Lower On Monday? ↗
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
News headline image
Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Scholar Rock Stock Raced 6% Higher Today ↗
A pundit at an influential U.S. bank is quite bullish on the company's future. 
Via The Motley Fool
News headline image
This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.